← All trials
NCT04467697
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2018
- Primary completion
- May 1, 2020
- Completion date
- May 1, 2020
- First posted
- Jul 13, 2020
- Last posted
- Jul 13, 2020
- Enrollment
- 173
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Marius PharmaceuticalsLead sponsor
- Syneos HealthCollaborator
- Syneos HealthStudy director
- Marius PharmaceuticalsStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.